Analysis of factors of production in the termination of feedlot lambs to pasture

ABSTRACT The objective of this study was to analyze the factors that influence the performance of lambs in pasture confinement, by substituting a concentrate with different levels of the aerial part of cassava in relation to hematocrit indices. The experiment was conducted at the Sheep Technology Center using 56 Pantaneira sheep, of which 28 were male and 28 were female. For female lambs, the globular volume showed a decreasing quadratic effect, with a minimum inclusion of 10.24% PAM in the diet for a hematocrit index of 32.28. A linear effect was observed for the mean crude protein intake in the male lambs based on the diet provided and was estimated to be equivalent to 87.4% of the lambs’ final weight. In conclusion, mean crude protein consumption is most strongly correlated with the final weight of male lambs, and NDF is most strongly correlated with the final weight of female lambs, with the level of cyanide consumption influencing the average daily weight gain in female lambs. The hematocrit level of the male lambs decreased with an increase in the inclusion of the aerial part of cassava in the ration of the animals

Perdas de solo, água, nutrientes e carbono orgânico em Cambissolo e Latossolo sob chuva natural Soil, water, nutrients and organic carbon losses from inceptisol and Oxisol under natural rainfall

A erosão hídrica é responsável por perdas de nutrientes e carbono dos solos agrícolas. A minimização das perdas de solo, água, nutrientes e carbono orgânico constitui importante aspecto do planejamento conservacionista. Os objetivos deste trabalho foram avaliar as perdas, por erosão hídrica, de solo, água, nutrientes e carbono orgânico em Cambissolo Háplico Tb distrófico típico (CXbd) e Latossolo Vermelho distroférrico típico (LVdf). As coletas foram realizadas depois de cada evento de chuva considerada erosiva. As perdas médias anuais de solo foram de 205,65 Mg ha-1 para o CXbd e de 14,90 Mg ha-1 para o LVdf. As perdas médias anuais de água foram 369 mm para o CXbd e 113 mm para o LVdf, representando, respectivamente, 28,67% e 8,78% do total precipitado. Os atributos mineralógicos, químicos e físicos e o relevo de ocorrência desses solos explicam satisfatoriamente os resultados obtidos. O CXbd apresentou as maiores perdas de nutrientes e carbono orgânico. O carbono orgânico foi encontrado em maior quantidade no sedimento erodido, evidenciado pelo caráter seletivo da erosão.<br>Water erosion is responsible for considerable losses of nutrients and organic carbon from agricultural soils. The reduction of soil, water, nutrients and organic carbon losses constitutes an important aspect of the conservation planning. The objectives of this work were to evaluate the soil, water, nutrients and organic carbon losses from a Typic Dystrochept (TD) and a Rhodic Hapludox (RH). The samplings were performed after each considered erosive rain event. The mean annual soil losses were 205.65 Mg ha-1 for the TD and 14.90 Mg ha-1 for the RH. The mean annual water losses were 369 mm for the TD and 113 mm for the RH, representing 28.67% and 8.78% of the total precipitation, respectively. The mineralogical, chemical and physical attributes and the relief where these soils occur satisfactorily explain the obtained results. The TD presents higher nutrients and organic carbon losses than the RH. The organic carbon was the main component of the eroded sediment, evidenced by the selective character of erosion

Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

Cardiolog

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

The authors thank the patients, study coordinators, and investigators who participated in this trial; and Sophie Rushton-Smith, PhD (MedLink Healthcare Communications, London), for providing editorial assistance in the preparation of the manuscript (limited to editing for style, referencing, and figure and table editing).BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths. OBJECTIVES This pre-specified analysis determined the extent to which alirocumab reduced total (first and subsequent) nonfatal cardiovascular events and all-cause deaths in ODYSSEY OUTCOMES. METHODS Hazard functions for total nonfatal cardiovascular events (myocardial infarction, stroke, ischemia-driven coronary revascularization, and hospitalization for unstable angina or heart failure) and death were jointly estimated, linked by a shared frailty accounting for patient risk heterogeneity and correlated within-patient nonfatal events. An association parameter also quantified the strength of the linkage between risk of nonfatal events and death. The model provides accurate relative estimates of nonfatal event risk if nonfatal events are associated with increased risk for death. RESULTS With 3,064 first and 5,425 total events, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed with alirocumab compared with placebo. Alirocumab reduced total nonfatal cardiovascular events (hazard ratio: 0.87; 95% confidence interval: 0.82 to 0.93) and death (hazard ratio: 0.83; 95% confidence interval: 0.71 to 0.97) in the presence of a strong association between nonfatal and fatal event risk. CONCLUSIONS In patients with ACS, the total number of nonfatal cardiovascular events and deaths prevented with alirocumab was twice the number of first events prevented. Consequently, total event reduction is a more comprehensive metric to capture the totality of alirocumab clinical efficacy after ACS

Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for >= 3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P= 100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; P-interaction=0.007). In the alirocumab group, all-cause death declined with achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for >= 3 years, if baseline LDL-C is >= 100 mg/dL, or if achieved LDL-C is low.Cardiolog